Literature DB >> 16230428

Is there any place for oral anti-restenotic treatment in the era of drug eluting stents?

A H Gershlick.   

Abstract

Are drug eluting stents destined to become the standard of care for all patients undergoing percutaneous coronary intervention, or are alternative therapeutic approaches preferable under certain circumstances?

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16230428      PMCID： PMC1769181          DOI： 10.1136/hrt.2005.060954

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


  10 in total

1.  Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.

Authors:  Eugène P McFadden; Eugenio Stabile; Evelyn Regar; Edouard Cheneau; Andrew T L Ong; Timothy Kinnaird; William O Suddath; Neil J Weissman; Rebecca Torguson; Kenneth M Kent; August D Pichard; Lowell F Satler; Ron Waksman; Patrick W Serruys
Journal:  Lancet       Date:  2004 Oct 23-29       Impact factor: 79.321

2.  Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators.

Authors:  A Rodriguez; V Bernardi; J Navia; J Baldi; L Grinfeld; J Martinez; D Vogel; R Grinfeld; A Delacasa; M Garrido; R Oliveri; E Mele; I Palacios; W O'Neill
Journal:  J Am Coll Cardiol       Date:  2001-01       Impact factor: 24.094

3.  Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study).

Authors:  Francesco Versaci; Achille Gaspardone; Fabrizio Tomai; Flavio Ribichini; Paolo Russo; Igino Proietti; Anna Silvia Ghini; Valeria Ferrero; Luigi Chiariello; Pier Agostino Gioffrè; Francesco Romeo; Filippo Crea
Journal:  J Am Coll Cardiol       Date:  2002-12-04       Impact factor: 24.094

4.  Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial).

Authors:  A E Rodríguez; M Rodríguez Alemparte; C F Vigo; C Fernández Pereira; C Llauradó; D Vetcher; A Pocovi; J Ambrose
Journal:  Heart       Date:  2005-03-17       Impact factor: 5.994

5.  Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease.

Authors:  P W Serruys; F Unger; J E Sousa; A Jatene; H J Bonnier; J P Schönberger; N Buller; R Bonser; M J van den Brand; L A van Herwerden; M A Morel; B A van Hout
Journal:  N Engl J Med       Date:  2001-04-12       Impact factor: 91.245

6.  Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-09-28       Impact factor: 79.321

7.  Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS).

Authors:  Joachim Schofer; Michael Schlüter; Anthony H Gershlick; William Wijns; Eulogio Garcia; Erick Schampaert; Günter Breithardt
Journal:  Lancet       Date:  2003-10-04       Impact factor: 79.321

8.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

Authors:  Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245

9.  Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study.

Authors:  Ron Waksman; Andrew E Ajani; Augusto D Pichard; Rebecca Torguson; Ellen Pinnow; Daniel Canos; Lowell F Satler; Kenneth M Kent; Pramod Kuchulakanti; Chrysoula Pappas; Louise Gambone; Neil Weissman; Maureen C Abbott; Joseph Lindsay
Journal:  J Am Coll Cardiol       Date:  2004-10-06       Impact factor: 24.094

10.  Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial.

Authors:  Jörg Hausleiter; Adnan Kastrati; Julinda Mehilli; Michael Vogeser; Dietlind Zohlnhöfer; Helmut Schühlen; Christoph Goos; Jürgen Pache; Franz Dotzer; Gisela Pogatsa-Murray; Josef Dirschinger; Uwe Heemann; Albert Schömig
Journal:  Circulation       Date:  2004-08-09       Impact factor: 29.690
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.